PCMK
LAB icon

Paragon Capital Management (Kansas)’s Standard BioTools LAB Stock Holding History

Paragon Capital Management (Kansas)’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-454
Closed -$6K – 271
2019
Q1 		$6K Buy
+454
New +$4.79K ﹤0.01% 187

Other funds holding LAB

EIP
Easterly Investment Partners Beverly, Massachusetts $1.31B AUM 18.17% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Paragon Capital Management (Kansas)'s LAB Position: Q2 2019 in Review

Paragon Capital Management (Kansas) sold out of Standard BioTools (LAB) in Q2 2019, closing a stake of 454 shares — an estimated $6K sold.

Paragon Capital Management (Kansas) first reported a position in LAB in Q1 2019 and held it in 1 quarter. The position peaked at $6K in Q1 2019. 135 funds tracked by Wall St. Rank hold LAB as of Q2 2019.

  • Paragon Capital Management (Kansas) reported no remaining Standard BioTools position as of Q2 2019 after selling out during the quarter.
  • Paragon Capital Management (Kansas) sold 454 Standard BioTools shares in Q2 2019, an estimated $6K.
  • Paragon Capital Management (Kansas) first reported a position in Standard BioTools in Q1 2019 and held it in 1 quarter.
  • Paragon Capital Management (Kansas)'s Standard BioTools position peaked at $6K in Q1 2019.
  • 135 funds tracked by Wall St. Rank held Standard BioTools as of Q2 2019.

Based on Paragon Capital Management (Kansas)'s 13F filing for Q2 2019, filed 6 Aug 2019.